TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02602795

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: The intervention is based on Acceptance and Commitment Therapy and will be tailored to help participants develop target adaptive responses to negative affect and other negative internal stimuli related to opioid detoxification.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Motivation Behavioral Model
Description: This intervention is based on the Information Motivation Behavior model for HIV/STI risk reduction and is tailored to more directly address HIV/STI risk among opioid dependent patients.
Study: NCT00510263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone + placebo
Description: Prednisolone 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Placebo 2 tablets 3 times daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valaciclovir + placebo
Description: Valaciclovir 500 mg 2 tablets 3 times daily for 7 days. Placebo tablets 12 per day for 5 days, tapering 2 tablets per day until day 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone + valaciclovir
Description: Prednisolone 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Valaciclovir 500 mg 2 tablets 3 times daily for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + placebo
Description: Placebo 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Placebo 2 tablets 3 times daily for 7 days.
Study: NCT05117879

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cold snaring polypectomy/ Cold EMR/Hot EMR
Description: Cold snaring polypectomy: The technique of cold snare polypectomy is used to remove \[small colonic polyps\] without diathermy, which implies that a polyp is transected by a snare along with a rim of surrounding normal mucosa.~Cold EMR: Cold EMR technique comprising submucosal injection of succinylated gelatin and dilute methylene blue before piecemeal cold snare resection of target polyp with a margin of normal tissue.~Hot EMR: Hot EMR technique comprising submucosal injection of succinylated gelatin and dilute methylene blue before piecemeal electrocautery snare resection of target polyp with a margin of normal tissue.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cold snaring polypectomy/ Cold EMR/Hot EMR
Description: Cold snaring polypectomy: The technique of cold snare polypectomy is used to remove \[small colonic polyps\] without diathermy, which implies that a polyp is transected by a snare along with a rim of surrounding normal mucosa.~Cold EMR: Cold EMR technique comprising submucosal injection of succinylated gelatin and dilute methylene blue before piecemeal cold snare resection of target polyp with a margin of normal tissue.~Hot EMR: Hot EMR technique comprising submucosal injection of succinylated gelatin and dilute methylene blue before piecemeal electrocautery snare resection of target polyp with a margin of normal tissue.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cold snaring polypectomy/ Cold EMR/Hot EMR
Description: Cold snaring polypectomy: The technique of cold snare polypectomy is used to remove \[small colonic polyps\] without diathermy, which implies that a polyp is transected by a snare along with a rim of surrounding normal mucosa.~Cold EMR: Cold EMR technique comprising submucosal injection of succinylated gelatin and dilute methylene blue before piecemeal cold snare resection of target polyp with a margin of normal tissue.~Hot EMR: Hot EMR technique comprising submucosal injection of succinylated gelatin and dilute methylene blue before piecemeal electrocautery snare resection of target polyp with a margin of normal tissue.
Study: NCT02151578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home/community case management

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home/community case management
Study: NCT04938622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sedentary Control
Description: Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories sufficient to maintain body weight. Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercising control
Description: Exercise: Participants engaged in supervised exercise training in Noll Laboratory Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories sufficient to maintain body weight and additional calories to remain in energy balance. Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15 percent energy deficit
Description: Exercise: Participants engaged in supervised exercise training in Noll Laboratory that was equal to 15 percent of the participants' daily caloric needs.~Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories to meet metabolic needs (before 15 percent deficit exercise). Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30 percent energy deficit
Description: Exercise: Participants engaged in supervised exercise training in Noll Laboratory that was equal to 30 percent of the participants' daily caloric needs.~Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories to meet metabolic needs (before 30 percent deficit exercise). Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30 percent energy deficit (15/15)
Description: Exercise: Participants engaged in supervised exercise training in Noll Laboratory that was equal to 15 percent of the participants' daily caloric needs.~Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had 15 percent less calories than those needed to meet metabolic needs. Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 60 percent energy deficit
Description: Exercise: Participants engaged in supervised exercise training in Noll Laboratory that was equal to 30 percent of the participants' daily caloric needs.~Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had 30 percent less calories than those needed to meet metabolic needs. Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein.
Study: NCT04451031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LiFT Program
Study: NCT03746483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS1819
Description: MS1819, an oral, non-systemic, that is non-enterically-coated. It is a yeast-derived (non-porcine) lipase pancreatic enzyme replacement.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS1819
Description: MS1819, an oral, non-systemic, that is non-enterically-coated. It is a yeast-derived (non-porcine) lipase pancreatic enzyme replacement.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Porcine PERT
Description: Porcine PERT is being used as a comparator to MS1819 as a second drug/intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Porcine PERT
Description: Porcine PERT is being used as a comparator to MS1819 as a second drug/intervention
Study: NCT02467049

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ECG-guided insertion of PICC
Description: Comparison of placement of a PICC (Peripherally Inserted Central Catheter) by ECG-guidance vs. ULTRASOUND-guidance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG-guided insertion of PICC
Description: Comparison of placement of a PICC (Peripherally Inserted Central Catheter) by ECG-guidance vs. ULTRASOUND-guidance
Study: NCT00101036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00250458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Rizatriptan
Description: One dose Rizatriptan 10 mg orally disintegrating tablet / oral lyophilisate to treat one migraine attack.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: One dose matching placebo to Rizatriptan to treat one migraine attack.
Study: NCT04482595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO 300 Oral Suspension
Description: Suspension of genistein nanoparticles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo for BIO 300 Oral Suspension
Study: NCT00943670

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pertuzumab
Description: Intravenous repeating dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine [Kadcyla]
Description: Intravenous repeating dose
Study: NCT03897114

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cocoa group
Description: Athletes perform the same training program and they take 5 g of cocoa (83 mg of flavonoids per gram of cocoa) mixed with low-fat milk for 10 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: The athletes perform the same training program and they take for 10 weeks 5 g maltodextrin mixed with low-fat milk for 10 weeks
Study: NCT00979524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Mental Health Services and Supports
Description: This study uses a quasi-experimental design to test the efficacy of a comprehensive mental health intervention to improve the mental health and employment outcomes of young adults (18-24) enrolling in the Eastside YO Program. Newly enrolling Eastside YO members will receive an array of mental health education and services based on level of need and serve as this study's intervention group. Newly enrolling Westside YO members will receive usual care services delivered by the staff at the Westside YO Program and serve as this study's comparison group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive Mental Health Services and Supports
Description: This study uses a quasi-experimental design to test the efficacy of a comprehensive mental health intervention to improve the mental health and employment outcomes of young adults (18-24) enrolling in the Eastside YO Program. Newly enrolling Eastside YO members will receive an array of mental health education and services based on level of need and serve as this study's intervention group. Newly enrolling Westside YO members will receive usual care services delivered by the staff at the Westside YO Program and serve as this study's comparison group.
Study: NCT03647774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended release naltrexone
Description: 380mg injectable extended release naltrexone every four weeks
Study: NCT03005431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent training and support
Description: Parents will be given access to participate in an on-line support forum and a set of on-line parent training modules.
Study: NCT00103922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilomilast
Study: NCT03982446

Intervention type: GENETIC
Intervention: Mutations

Intervention type: GENETIC
Intervention: Mutations
Study: NCT06225154

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Description: Non-surgical periodontal treatment was performed in a quadrant-wise manner at 1-week intervals.
Study: NCT02180997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Tamsulosin and solifenacin: Tamsulosin 0.4mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Tamsulosin and solifenacin: Tamsulosin 0.4mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Tamsulosin and solifenacin: Tamsulosin 0.4mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Tamsulosin and solifenacin: Tamsulosin 0.4mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: Tamsulosin and solifenacin: Solifenacin 10 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: Tamsulosin and solifenacin: Solifenacin 10 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: Tamsulosin and solifenacin: Solifenacin 10 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: Tamsulosin and solifenacin: Solifenacin 10 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin and solifenacin
Description: Tamsulosin and solifenacin: Tamsulosin 0.4mg, once daily, Solifenacin 10 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin and solifenacin
Description: Tamsulosin and solifenacin: Tamsulosin 0.4mg, once daily, Solifenacin 10 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin and solifenacin
Description: Tamsulosin and solifenacin: Tamsulosin 0.4mg, once daily, Solifenacin 10 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin and solifenacin
Description: Tamsulosin and solifenacin: Tamsulosin 0.4mg, once daily, Solifenacin 10 mg, once daily
Study: NCT01897662

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NUTRIOSE FB06
Description: 14g/day NUTRIOSE FB06: 7g in 250 mL orange juice twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GLUCIIDEX 21
Description: 7g/day GLUCIDEX 21 : 3.5g in 250 mL orange juice twice a day
Study: NCT01113138

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mablet (Magnesium-supplement)
Description: Mablet: Magnesium hydroxide/ -oxide (360 mg/tablet) 3 tablets as a single dose Produced by: Gunnar Kjems APS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Solution for a single bolus-infusion, containing 2 grams of magnesium sulfate.
Study: NCT03469180

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill training
Description: Treadmill training Each season will be supervised and last 45 minutes. Treadmill speed will be adjusted to the child's maximal heart rate (MHR) (between 65 to 75 percent of the MHR).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill training
Description: Treadmill training Each season will be supervised and last 45 minutes. Treadmill speed will be adjusted to the child's maximal heart rate (MHR) (between 65 to 75 percent of the MHR).
Study: NCT02467049

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ULTRASOUND-guided insertion of PICC
Description: Comparison of placement of a PICC (Peripherally Inserted Central Catheter) by ECG-guidance vs. ULTRASOUND-guidance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ULTRASOUND-guided insertion of PICC
Description: Comparison of placement of a PICC (Peripherally Inserted Central Catheter) by ECG-guidance vs. ULTRASOUND-guidance
Study: NCT01951261

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Telemonitoring and telephone control
Description: Early assisted discharge from hospital due to an exacerbation of chronic obstructive pulmonary disease, with telemonitoring of vitals signs (oxygen saturation, heart rate, respiratory rate, blood pressure, temperature and electrocardiogram)and telephone control dairy (morning, evening)by the pulmonologist.
Study: NCT02730676

Intervention type: OTHER
Intervention: Electronic Cigarette #1
Description: VUSE® Digital Vapor Cigarettes (original flavor, 29 mg nicotine)

Intervention type: OTHER
Intervention: Electronic Cigarette #2
Description: VUSE® Digital Vapor Cigarettes (menthol flavor, 29 mg nicotine)
Study: NCT00983424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporins
Description: dose escalation, administered orally twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: 100 mg/m2 IV days 1, 8 and 15
Study: NCT04161547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSPCHA115 100 mg; Matching placebo 100 mg
Description: CSPCHA115 100 mg once daily in the fasted state for 7 days; Matching placebo 100 mg once daily in the fasted state for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSPCHA115 200 mg; Matching placebo 200 mg
Description: CSPCHA115 200 mg once daily in the fasted state for 7 days; Matching placebo 200 mg once daily in the fasted state for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSPCHA115 400 mg; Matching placebo 400 mg
Description: CSPCHA115 400 mg once daily in the fasted state for 7 days; Matching placebo 400 mg once daily in the fasted state for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSPCHA115 600 mg; Matching placebo 600 mg
Description: CSPCHA115 600 mg once daily in the fasted state for 7 days; Matching placebo 600 mg once daily in the fasted state for 7 days.
Study: NCT03223714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conbercept Ophthalmic Injection
Description: Subject receive 0.5 mg Conbercept injection into their study eyes every month (Day 0 - Month 5).~If subjects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 \~ 11).

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Conbercept Ophthalmic Injection
Description: Subject receive 0.5 mg Conbercept injection into their study eyes every month (Day 0 - Month 5).~If subjects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 \~ 11).

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: sham injection
Description: Subjects receive sham injection into their study eyes every month (Day 0 - Month 5).~Subjects receive a single intravitreal injection of 0.5 mg Conbercept ophthalmic injection in month 6, followed monthly review, if he/she meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 \~ 11).
Study: NCT03469180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration training
Description: Whole body vibration training whole body vibration frequence will be 50 Hertz and childrens will be standing position on vibration platform .
Study: NCT05336292

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meaningful life-focused intervention
Description: The intervention works different skills to increase the meaningful life in the general population and specifically in the army.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meaningful life-focused intervention
Description: The intervention works different skills to increase the meaningful life in the general population and specifically in the army.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meaningful life-focused intervention
Description: The intervention works different skills to increase the meaningful life in the general population and specifically in the army.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meaningful life and emotional regulation-focused intervention
Description: The intervention works different skills to increase the meaningful life and emotional regulation in the general population and specifically in the army.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meaningful life and emotional regulation-focused intervention
Description: The intervention works different skills to increase the meaningful life and emotional regulation in the general population and specifically in the army.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meaningful life and emotional regulation-focused intervention
Description: The intervention works different skills to increase the meaningful life and emotional regulation in the general population and specifically in the army.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: This group does not do any intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: This group does not do any intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: This group does not do any intervention
Study: NCT03008993

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HQIS implementation
Study: NCT04364113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Protein Diet
Description: The usual protein diet contains 1.30 g/kg/day protein and 16-20 mg/kg/day of Phosphorus

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Protein Diet
Description: The usual protein diet contains 1.30 g/kg/day protein and 16-20 mg/kg/day of Phosphorus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Protein Diet
Description: The low protein diet contains 0.575 g/kg/day protein and 5-10 mg/kg/day of Phosphorus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Protein Diet
Description: The low protein diet contains 0.575 g/kg/day protein and 5-10 mg/kg/day of Phosphorus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Protein Diet
Description: The low protein diet contains 0.575 g/kg/day protein and 5-10 mg/kg/day of Phosphorus

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Protein Diet
Description: The low protein diet contains 0.575 g/kg/day protein and 5-10 mg/kg/day of Phosphorus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very Low Protein Diet
Description: The very low protein diet contains 0.28 g/kg/day or protein, mg/kg/day of Phosphorus and a keto acid mixture.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very Low Protein Diet
Description: The very low protein diet contains 0.28 g/kg/day or protein, mg/kg/day of Phosphorus and a keto acid mixture.
Study: NCT00078858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic PBMC transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo allogeneic PBMC transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given PO